NO20032142L - Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister - Google Patents

Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister

Info

Publication number
NO20032142L
NO20032142L NO20032142A NO20032142A NO20032142L NO 20032142 L NO20032142 L NO 20032142L NO 20032142 A NO20032142 A NO 20032142A NO 20032142 A NO20032142 A NO 20032142A NO 20032142 L NO20032142 L NO 20032142L
Authority
NO
Norway
Prior art keywords
phenylaminoimidazoline
antagonists
substituted
phenylketone derivatives
phenylketone
Prior art date
Application number
NO20032142A
Other languages
English (en)
Other versions
NO20032142D0 (no
Inventor
Alam Jahangir
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20032142D0 publication Critical patent/NO20032142D0/no
Publication of NO20032142L publication Critical patent/NO20032142L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20032142A 2000-11-14 2003-05-13 Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister NO20032142L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24888800P 2000-11-14 2000-11-14
PCT/EP2001/012776 WO2002040453A1 (en) 2000-11-14 2001-11-05 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists

Publications (2)

Publication Number Publication Date
NO20032142D0 NO20032142D0 (no) 2003-05-13
NO20032142L true NO20032142L (no) 2003-05-13

Family

ID=22941114

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032142A NO20032142L (no) 2000-11-14 2003-05-13 Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister

Country Status (29)

Country Link
EP (1) EP1339694B1 (no)
JP (1) JP4108474B2 (no)
KR (1) KR100562605B1 (no)
CN (1) CN1267423C (no)
AR (1) AR035502A1 (no)
AT (1) ATE305002T1 (no)
AU (1) AU2180802A (no)
BG (1) BG107814A (no)
BR (1) BR0115291A (no)
CA (1) CA2427900A1 (no)
CZ (1) CZ20031596A3 (no)
DE (1) DE60113563T2 (no)
EC (1) ECSP034602A (no)
ES (1) ES2248413T3 (no)
HU (1) HUP0303156A3 (no)
IL (1) IL155436A0 (no)
MA (1) MA26958A1 (no)
MX (1) MXPA03004073A (no)
NO (1) NO20032142L (no)
NZ (1) NZ525330A (no)
PA (1) PA8532201A1 (no)
PE (1) PE20020602A1 (no)
PL (1) PL362549A1 (no)
RU (1) RU2284995C2 (no)
SK (1) SK7222003A3 (no)
UY (1) UY27023A1 (no)
WO (1) WO2002040453A1 (no)
YU (1) YU37203A (no)
ZA (1) ZA200303413B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071508A1 (en) * 2003-02-14 2004-08-26 Medical Research Council Ip receptor antagonists for the treatment of pathological uterine conditions
KR100777876B1 (ko) * 2003-05-01 2007-11-28 에프. 호프만-라 로슈 아게 프로스타글란딘 ｉ2(ｉｐ) 길항제로서 이미다졸린-2-일아미노페닐 아마이드
JP2007521276A (ja) * 2003-06-25 2007-08-02 スミスクライン・ビーチャム・コーポレイション Ｎｋ−２およびｎｋ−３として用いるための４−カルボキサミドキノリン誘導体
MXPA06000269A (es) * 2003-07-09 2006-04-07 Hoffmann La Roche Tiofenilaminoimidazolinas.
JP2009524619A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置のための２−イミダゾールの使用
AU2007312390B2 (en) 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
AU2007316257A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles as modulators of the trace amine associated receptors
WO2008058867A2 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
KR101189348B1 (ko) 2006-12-13 2012-10-09 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체(ｔａａｒ)에 대한 리간드로서의 신규한 2-이미다졸
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
ES2510546T3 (es) 2007-02-02 2014-10-21 F. Hoffmann-La Roche Ag Nuevas 2-aminooxazolinas como ligandos TAAR1 para trastornos del SNC
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
CN101687812A (zh) 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
KR101150628B1 (ko) 2007-07-03 2012-05-31 에프. 호프만-라 로슈 아게 4-이미다졸린 및 항우울제로서 이의 용도
CN101765587A (zh) 2007-07-27 2010-06-30 弗·哈夫曼-拉罗切有限公司 作为taar配体的2-氮杂环丁烷甲胺类和2-吡咯烷甲胺类
KR101167773B1 (ko) 2007-08-03 2012-07-24 에프. 호프만-라 로슈 아게 Ｔａａｒ１ 리간드로서의 피리딘카복스아마이드 및 벤즈아마이드 유도체
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
EP2513064B1 (en) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2014143592A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid ip receptors
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
MY195528A (en) 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar
WO2022101435A1 (en) * 2020-11-12 2022-05-19 3Z Ehf Novel treatments of attention deficit/hyperactivity disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889868A (en) * 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
NZ331480A (en) * 1997-09-04 2000-02-28 F 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
YU37203A (sh) 2006-05-25
CN1474813A (zh) 2004-02-11
PA8532201A1 (es) 2002-08-26
JP2004513940A (ja) 2004-05-13
CN1267423C (zh) 2006-08-02
EP1339694B1 (en) 2005-09-21
SK7222003A3 (en) 2004-05-04
PE20020602A1 (es) 2002-07-08
JP4108474B2 (ja) 2008-06-25
MXPA03004073A (es) 2003-09-04
NO20032142D0 (no) 2003-05-13
ES2248413T3 (es) 2006-03-16
UY27023A1 (es) 2002-06-20
ZA200303413B (en) 2004-08-02
KR20030065512A (ko) 2003-08-06
PL362549A1 (en) 2004-11-02
DE60113563T2 (de) 2006-07-13
BG107814A (bg) 2004-02-27
CA2427900A1 (en) 2002-05-23
AR035502A1 (es) 2004-06-02
ECSP034602A (es) 2003-06-25
HUP0303156A2 (hu) 2004-01-28
IL155436A0 (en) 2003-11-23
NZ525330A (en) 2004-10-29
CZ20031596A3 (cs) 2004-01-14
KR100562605B1 (ko) 2006-03-17
BR0115291A (pt) 2003-08-19
RU2284995C2 (ru) 2006-10-10
HUP0303156A3 (en) 2004-03-29
DE60113563D1 (de) 2006-02-02
MA26958A1 (fr) 2004-12-20
WO2002040453A1 (en) 2002-05-23
EP1339694A1 (en) 2003-09-03
AU2180802A (en) 2002-05-27
ATE305002T1 (de) 2005-10-15

Similar Documents

Publication Publication Date Title
NO20032142D0 (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
NO20024387D0 (no) Karboksylsyrederivater som IP-antagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20030055D0 (no) Colchinolderivater som angiogenese inhibitorer
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
NO20023485L (no) 1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1360184T3 (da) Piperidinderivater som neurokinin-1-antagonister
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE334114T1 (de) Substituierte c-cyclohexylmethylamin-derivate
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
DK1322592T4 (da) Substituerede 1-aminobutan-3-ol-derivater
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DK1406888T3 (da) Substituerede gamma-lactonforbindelser som NMDA-antagonister
DK1261588T3 (da) Imidazolforbindelser som alfa2-adrenoceptorantagonister
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
DK1322590T3 (da) Substituerede 5-amino-1-penten-3-ol-derivater
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater
DK1210333T3 (da) p-Tolylsubstituerede heterocycliske forbindelser som herbicider
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application